Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 2/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388613 | 0.86 | KLKB1 (0.37) | PLGKLKB1FOLH1 | |
| SCHEMBL14129393 | 0.82 | OPRK1 (0.39) | CCKBRF11PLGKLKB1PLAU | |
| SCHEMBL12342513 | 0.82 | OPRK1 (0.39) | CCKBRF11PLGKLKB1PLAU | |
| SCHEMBL12342504 | 0.79 | TTR (0.44) | CCKBRF11PLGKLKB1PLAU | |
| SCHEMBL12377406 | 0.78 | CCKBR (0.39) | CCKBROPRK1FOLH1 | |
| SCHEMBL12342493 | 0.78 | OPRK1 (0.40) | CCKBRPLGKLKB1OPRK1FOLH1 | |
| SCHEMBL25795377 | 0.78 | CCKBR (0.40) | CCKBRPLGPRSS1PRSS2PRSS3 | |
| SCHEMBL18912653 | 0.77 | TTR (0.36) | — | |
| SCHEMBL22452311 | 0.77 | TTR (0.37) | PLGKLKB1FOLH1 | |
| SCHEMBL23005883 | 0.77 | TTR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312736-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11692038-B2 | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) | GILEAD SCIENCES, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312736-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, CCR4, CCR3 | CCKBR 2152/4885F11 1393/4885PLG 3778/4885 |
| US-11692038-B2 | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) | CCR8, CCR1, CCR3 | CCKBR 669/4885F11 1381/4885PLG 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.